Regen BioPharma, Inc. Researchers Identify Key Structure in Compounds that Activate NR2F6

SAN DIEGO, September 6, 2017 /PRNewswire/ --

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), in conjunction with its medicinal chemistry partner, ChemDiv, Inc., believes it has made a fundamental discovery in developing small molecule drugs that activate NR2F6. The Company reports that recently identified novel chemical compounds that activate NR2F6 have key structural elements that make them active and specific.  

The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.

"Our medicinal chemists have identified key structural elements in our most active and selective compounds that seem to confer these properties," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "Gaining structural insight into the mechanism of activation and specificity of these drugs paves the way forward for speeding optimization of these agonists, creating new drugs and securing a patent portfolio of chemical matter."

"With this new information, we feel that the agonist program is maturing rapidly," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc. "We anticipate to have an optimized agonist in the next 2 to 3 months and will be filing more composition of matter patents."

About Regen BioPharma Inc.:  

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
http://www.regenbiopharma.com
[email protected]

SOURCE Regen BioPharma, Inc.